Page 262 - Programme book for The International Liver Congress 2015, EASL ILC 2015
P. 262
Viral Hepatitis: Hepatitis C - Clinical (Therapy) (Cont.)
P0815 COST-EFFECTIVENESS OF TREATING DIFFERENT STAGES
OF GENOTYPE 1 HEPATITIS C VIRUS (HCV) WITH ABBVIE
3D (ABT-450/RITONAVIR/OMBITASVIR AND DASABUVIR) +/-
RIBAVIRIN COMPARED TO NO TREATMENT IN THE UNITED
STATES
Scott J. Johnson, Derek A. Misurski, Timothy R. Juday,
Jennifer C. Samp*, Steve E. Marx, Hélène Parisé, Suchin Virabhak,
Sammy Saab, The United States
P0816 REDUCTION IN ANNUAL MEDICAL COSTS WITH EARLY
TREATMENT OF HCV USING ABBVIE 3D (ABT-450/
RITONAVIR/OMBITASVIR AND DASABUVIR) +/- RIBAVIRIN
IN THE UNITED STATES
Derek A. Misurski, Scott J. Johnson, Jennifer C. Samp*, Steve E. Marx,
Timothy R. Juday, Suchin Virabhak, Hélène Parisé, Sammy Saab,
The United States
P0817 COST-EFFECTIVENESS OF TREATING CHRONIC HEPATITIS
C GENOTYPE-1 WITH LEDIPASVIR AND SOFOSBUVIR IN
ePOSTERS GERMANY
Jona T. Stahmeyer*, Siegbert Rossol, Florian Bert, Ines M. Guerra,
Christian Krauth, Germany
P0818 ANALYSIS OF NS3 PROTEASE RESISTANCE-ASSOCIATED
VARIANTS AND PHENOTYPES FOR THE PREDICTION OF
TREATMENT RESPONSE TO HCV TRIPLE THERAPY
Julia Dietz*, Daniel Rupp, Dany Perner, Caterina Berkowski,
Mirjam Räder, Simone Susser, Stefan Mauss, Thomas Kuntzen,
Stefan Zeuzem, Ralf Bartenschlager, Christoph Sarrazin, Germany
P0819 SIMEPREVIR AND SOFOSBUVIR WITH MODIFIED DOSES
OF RIBAVIRIN THERAPY ON TELAPREVIR EXPERIENCED
CO INFECTED (WITH HIV) CIRRHOTICS WITH CHRONIC
HEPATITIS C, A RANDOMIZED OPEN LABEL CLINICAL
PILOT STUDY: STOP C
P Patrick Basu*, Niraj J. Shah, Robert Brown Jr, The United States
P0820 PHARMACOKINETICS OF PARITAPREVIR, OMBITASVIR,
DASABUVIR, RITONAVIR AND RIBAVIRIN IN SUBJECTS
WITH HCV GENOTYPE 1 INFECTION IN PHASE 3 STUDIES
Sven Mensing, Shringi Sharma, Dörthe Eckert, Akshanth Polepally,
Amit Khatri*, Thomas Podsadecki, Walid Awni, Rajeev Menon,
Sandeep Dutta, The United States
262 The International Liver Congress™ 2015 • ILC Programme
P0815 COST-EFFECTIVENESS OF TREATING DIFFERENT STAGES
OF GENOTYPE 1 HEPATITIS C VIRUS (HCV) WITH ABBVIE
3D (ABT-450/RITONAVIR/OMBITASVIR AND DASABUVIR) +/-
RIBAVIRIN COMPARED TO NO TREATMENT IN THE UNITED
STATES
Scott J. Johnson, Derek A. Misurski, Timothy R. Juday,
Jennifer C. Samp*, Steve E. Marx, Hélène Parisé, Suchin Virabhak,
Sammy Saab, The United States
P0816 REDUCTION IN ANNUAL MEDICAL COSTS WITH EARLY
TREATMENT OF HCV USING ABBVIE 3D (ABT-450/
RITONAVIR/OMBITASVIR AND DASABUVIR) +/- RIBAVIRIN
IN THE UNITED STATES
Derek A. Misurski, Scott J. Johnson, Jennifer C. Samp*, Steve E. Marx,
Timothy R. Juday, Suchin Virabhak, Hélène Parisé, Sammy Saab,
The United States
P0817 COST-EFFECTIVENESS OF TREATING CHRONIC HEPATITIS
C GENOTYPE-1 WITH LEDIPASVIR AND SOFOSBUVIR IN
ePOSTERS GERMANY
Jona T. Stahmeyer*, Siegbert Rossol, Florian Bert, Ines M. Guerra,
Christian Krauth, Germany
P0818 ANALYSIS OF NS3 PROTEASE RESISTANCE-ASSOCIATED
VARIANTS AND PHENOTYPES FOR THE PREDICTION OF
TREATMENT RESPONSE TO HCV TRIPLE THERAPY
Julia Dietz*, Daniel Rupp, Dany Perner, Caterina Berkowski,
Mirjam Räder, Simone Susser, Stefan Mauss, Thomas Kuntzen,
Stefan Zeuzem, Ralf Bartenschlager, Christoph Sarrazin, Germany
P0819 SIMEPREVIR AND SOFOSBUVIR WITH MODIFIED DOSES
OF RIBAVIRIN THERAPY ON TELAPREVIR EXPERIENCED
CO INFECTED (WITH HIV) CIRRHOTICS WITH CHRONIC
HEPATITIS C, A RANDOMIZED OPEN LABEL CLINICAL
PILOT STUDY: STOP C
P Patrick Basu*, Niraj J. Shah, Robert Brown Jr, The United States
P0820 PHARMACOKINETICS OF PARITAPREVIR, OMBITASVIR,
DASABUVIR, RITONAVIR AND RIBAVIRIN IN SUBJECTS
WITH HCV GENOTYPE 1 INFECTION IN PHASE 3 STUDIES
Sven Mensing, Shringi Sharma, Dörthe Eckert, Akshanth Polepally,
Amit Khatri*, Thomas Podsadecki, Walid Awni, Rajeev Menon,
Sandeep Dutta, The United States
262 The International Liver Congress™ 2015 • ILC Programme
